Specify a stock or a cryptocurrency in the search bar to get a summary
Enveric Biosciences Inc
ENVBEnveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida. Address: 4851 Tamiami Trail North, Naples, FL, United States, 34103
Analytics
WallStreet Target Price
8.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ENVB
Dividend Analytics ENVB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ENVB
Stock Valuation ENVB
Financials ENVB
Results | 2019 | Dynamics |